Influenza-induced tachypnea is prevented in immune cotton rats, but cannot be treated with an anti-inflammatory steroid or a neuraminidase inhibitor.
Influenza viruses are one of the leading causes of morbidity and mortality during winter months. Increased respiratory rate (tachypnea) is a sign of increasing lower respiratory disease during influenza infection and is frequently observed in hospitalized patients. We investigated this clinical sign in influenza virus-infected cotton rats (Sigmodon hispidus) and the efficacy of antiviral and anti-inflammatory therapy in reducing symptomatic disease. Cotton rats infected intranasally with A/Wuhan/359/95 (H3N2) had increased respiratory rates from 1 to 4 days postinfection that correlated with the dose of virus used to inoculate the animal but not the amount of virus recovered from the lung. In addition, evaluation of sequential lung tissue pathology revealed that extensive epithelial cell destruction of small airways correlated with tachypnea. Increased respiratory rate was not observed in immune animals, supporting results that demonstrated a requirement for exposure to, and infection by, large amounts of live virus for induction of tachypnea. A variety of therapeutic approaches proved ineffective in reducing tachypnea, including anti-inflammatory therapy with systemic triamcinolone acetonide, bronchodilatory therapy with levalbuterol, or antiviral therapy with zanamivir. These results, together with the pathologic observations, suggest that early disruption of the lower respiratory tract epithelium is a major component of the pathophysiology of influenza infection. Therapeutic approaches need to be tailored to clear airway obstruction and restore an intact epithelium.
Eichelberger
Maryna C
MC
Virion Systems Inc., Rockville MD 21205, USA. MarynaE@virionsystems.com
Prince
Gregory A
GA
Ottolini
Martin G
MG
D000420:Albuterol / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000627:therapeutic use; D004195:Disease Models, Animal; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006146:Guanidines; D006801:Humans; D009980:Influenza A virus / Q000472:pathogenicity; D007251:Influenza, Human / Q000188:drug therapy / Q000276:immunology / Q000473:pathology* / Q000821:virology; D008297:Male; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D011714:Pyrans; D012120:Respiration Disorders / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D012794:Sialic Acids / Q000627:therapeutic use*; D016205:Sigmodontinae; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D053243:Zanamivir
D000893:Anti-Inflammatory Agents; D000998:Antiviral Agents; D001993:Bronchodilator Agents; D005938:Glucocorticoids; D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; D009439:Neuraminidase; D014222:Triamcinolone Acetonide; D053243:Zanamivir; D000420:Albuterol